Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A

Nature Genetics

Volumn 10, Issue 1, 1995, Pages 119-121

  Bi, L ^a   Lawler, A M ^b   Antonarakis, S E ^c   High, K A ^d   Gearhart, J D ^b   Kazazian, H H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ANIMAL CELL; ARTICLE; BLEEDING; CHIMERA; ENZYME ACTIVITY; GENE DISRUPTION; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENE THERAPY; HEMOPHILIA A; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; X CHROMOSOME LINKAGE;

ANIMAL; BASE SEQUENCE; BLOTTING, SOUTHERN; CELL LINE; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; EXONS; FACTOR VIII; FEMALE; HEMOPHILIA A; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; POLYMERASE CHAIN REACTION; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029011723     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng0595-119     Document Type: Article

References (28)

1. Rizza, C. R. & Spooner, R. J. D. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-1980: Report on behalf of the Directors of Haemophilia Centres in the United Kingdom. Br. med. J. 286, 391-402 (1983).
2. Sadler, J. E. & Davie, E. W. Haemophilia A, haemophilia B and von Willebrand’s disease. in The Molecular Basis of Blood Disease. (eds Stamatoyanopoulos, G. et al.) 575-630 (W. B. Saunders, Philadelphia, 1987).
3. Kazazian, H. H. Jr., Tuddenham, E. G. D. & Antonarakis, S. E. Haemophilia A and parahaemophilia: deficiencies of factors VIII and V. in Medical and Metabolic Basis of Inherited Disease, 7th edn (eds Scriver, C. et al.) 3241-3267 (McGraw-Hill, New York, 1995).
4. Graham, J. B. & Brinkhous, K. M. Canine and equine haemophillia, in Hand book of Haemophilia (eds Graham, J. B. et al) (Elsevier, New York, 1975).
5. Evans, J. P. et al. Canine haemophilia B resulting from a point mutation with unusual consequences. Proc. natn. Acad. Sci. U. S. A. 86, 10095-10099 (1989).
6. St Louis, D. & Verma, I. M. An alternative approach to somatic gene therapy. Proc. natn. Acad. Sci. U. S. A. 85, 3150-3154 (1988).
7. Kay, M. A. et al. In vivo gene therapy of haemophilia B: Sustained partial correction in factor IX-deficient dogs. Science 262, 117-119 (1993).
8. Kay, M. A. et al. in vivo hepatic gene therapy: Complete albiet transient correction of factor IX deficiency in haemophilia B dogs. Proc. natn. Acad. Sci. U. S. A. 91, 2353-2357 (1994).
9. Gitschier, J. et al. Characterization of the human factor VIII gene. Nature312, 326-330 (1984).
10. Wood, W. I. et al. Expression of active human factor VIII from recombinant DNA clones. Nature 312, 330-337 (1984).
11. Vehar, G. A. et al. Structure of human factor VIII. Nature 312, 337-342 (1984).
12. Toole, J. J. et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312, 342-347 (1984).
13. Wion, K. L. et al. Distribution of factor VIII: mRNA and antigen in human liver and other tissues. Nature 317, 726-728, (1985).
14. Lakich, D., Kazazian, H. H. Jr, Antonarakis, S. E. & Gitschier, J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nature Genet. 5, 236-241 (1993).
15. Naylor, J. A., Brinke, A., Hassock, S., Green, P. M. & Giannelli, F. Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large gene inversions. Hum. molec. Genet. 2, 1773-1778 (1993).
16. Rossiter, J. P. et al. Factor VIII gene inversions causing severe haemophilia A originate almost exclusively in male germ cells. Hum. molec. Genet. 3, 1035-1039, (1994).
17. Antonarakis, S. E., Kazazian, H. H. Jr. & Tuddenham, E. G. D. Molecular etiology of factor VIII deficiency in haemophilia A. Hum. Mut. 5, 1-22 (1995).
18. Hoyer, L. W. & Scandella, D. Factor VIII inhibitors: Structure and function in autoantibody and haemophilia A patients. Sem. hematol. 31, 1-5 (1994).
19. Aledort, L. Inhibitors in haemophilia patients: Current status and management. Am. j. Hematol. 47, 208-217 (1994).
20. Sambrook, J., Fritsch, E. F. & Maniatis, T. Molecular cloning, a laboratory manual. 2nd edn (Cold Spring Harbor Laboratory Press, 1989).
21. Deng, W. P. & Nickoloff, J. A. Site-directed mutagenesis of virtually any plasmid by eliminating a unique site. Anal. Biochem. 200, 81-89 (1992).
22. Wassarman, P. M. & DePamphilis, M. L. Guide to techniques in mouse development. Meth. Enzymol. 225, 803-879 (1993).
23. Saiki, R. K. et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239, 487-491 (1988).
24. Rosen, S. et al. Clinical application of a chromogenic substrate method for determination of factor VIII activity. Thomb. Haem. 54, 818-823 (1985).
25. Proctor, R. R. & Rapaport, S. I. The partial thromboplastin time with kaolin: Simple screening test for first stage plasma factor deficiencies. Am. J. Clin. Pathol. 36, 212-218 (1961).
26. Elder, B., Lakich, D. & Gitschier, J. Sequence of the murine factor VIII cDNA. Genomics 16, 374-379 (1993).
27. Thomas, K. R. & Capecchi, M. R. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51, 503-512 (1987).
28. Soriano, P., Montgomery, C., Geske, R. & Bradley, A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64, 693-702 (1991).